Skip to main content
AAN.com

Abstract

Background: Mutations in the early growth response 2 (EGR2) gene have recently been found in patients with congenital hypomyelinating neuropathy and Charcot-Marie-Tooth type 1 (CMT1) disease.
Objective: To determine the frequency of EGR2 mutations in patients with a diagnosis of CMT1, Dejerine–Sottas syndrome (DSS), or unspecified peripheral neuropathies.
Methods: Fifty patients and 70 normal control subjects were screened.
Results: A de novo missense mutation (Arg359Trp) in the α-helix of the first zinc-finger domain of the EGR2 transcription factor was identified in a patient diagnosed with a clinical phenotype consistent with DSS. This patient had a motor median nerve conduction velocity of 8 m/s. A sural nerve biopsy showed a severe loss of myelinated and unmyelinated fibers, evidence for demyelination, numerous classic onion bulbs, and focally folded myelin sheaths. DSS is a severe, childhood-onset demyelinating peripheral neuropathy initially thought to be inherited as an autosomal recessive trait. However, several dominant heterozygous mutations in the peripheral myelin protein 22 (PMP22) gene and dominant mutations in the peripheral myelin protein zero (MPZ) gene, both in the heterozygous and homozygous state, have been reported in patients with DSS.
Conclusions: Hereditary peripheral neuropathies represent a spectrum of disorders due to underlying defects in myelin structure or formation.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
De Jonghe P, Timmerman V, Nelis E, Martin J-J, Van Broeckhoven C. Charcot-Marie-Tooth disease and related peripheral neuropathies. J Peripheral Nerv Syst 1997;2:370–387.
2.
Nelis E, Haites N, Van Broeckhoven C. Mutations in the peripheral myelin genes and associated genes in inherited peripheral neuropathies. Hum Mutat 1999;13:11–28.
3.
Warner LE, Mancias P, Butler IJ, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 1998;18:382–384.
4.
Joseph LJ, Le Beau MM, Jamieson Jr GA, et al. Molecular cloning, sequencing, and mapping of EGR2, a human early growth response gene encoding a protein with “zinc-binding finger” structure. Proc Natl Acad Sci USA 1988;85:7164–7168. (See erratum Proc Natl Acad Sci USA 1989;86:515.)
5.
Rangnekar VM, Aplin A, Sukhatme VP. The serum and TPA responsive promotor and intron-exon structure of EGR2, a human early growth response gene encoding an zinc finger protein. Nucleic Acids Res 1990;18:2749–2757.
6.
Sham MH, Vesque C, Nonchev S, et al. The zinc finger gene Krox20 regulates HoxB2 (Hox2.8) during hindbrain segmentation. Cell 1993;72:183–196.
7.
Topilko P, Schneider-Maunoury S, Levi G, et al. Krox-20 controls myelination in the peripheral nervous system. Nature 1994;371:796–799.
8.
Swiatek PJ, Gridley T. Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene Krox-20. Genes Dev 1993;7:2071–2084.
9.
Navon R, Timmerman V, Löfgren A, et al. Prenatal diagnosis of Charcot-Marie-Tooth disease type 1A (CMT1A) using molecular genetic techniques. Prenat Diagn 1995;15:633–640.
10.
Nelis E, Warner LE, De Vriendt E, Chance PF, Lupski JR, Van Broeckhoven C. Comparison of single-strand conformation polymorphism and heteroduplex analysis for detection of mutations in Charcot-Marie-Tooth type 1 disease and related peripheral neuropathies. Eur J Hum Genet 1996;4:329–333.
11.
Nelis E, Simokovic S, Timmerman V, et al. Mutation analysis of the connexin32 (Cx32) gene in Charcot-Marie-Tooth neuropathy type 1 : identification of five new mutations. Hum Mutat 1997;9:47–52.
12.
Dejerine J, Sottas J. Sur la névrite interstitielle, hypertrophique et progressive de l’enfance. CR Soc Biol (Paris) 1893;45:63–96.
13.
Dyck PJ, Chance P, Lebo R, Carney JA. Hereditary motor and sensory neuropathies. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, eds. Peripheral neuropathy. 3rd ed. Philadelphia:WB Saunders, 1993:1094–1136.
14.
Lupski JR. Molecular genetics of peripheral neuropathies. In: Martin JB, ed. Scientific American molecular neurology. New York:Scientific American, 1998:239–256.
15.
Warner LE, Garcia CA, Lupski JR. Hereditary peripheral neuropathies : clinical forms, genetics and molecular mechanisms. Annu Rev Med 1999;50:263–275.
16.
Tyson J, Ellis D, Fairbrother U, et al. Hereditary demyelinating neuropathy of infancy : a genetically complex syndrome. Brain 1997;120:47–63.
17.
Nardelli J, Gibson TJ, Vesque C, Charnay P. Base sequence discrimination by zinc-finger DNA-binding domains. Nature 1991;349:175–178.
18.
Pavletich NP, Pabo CO. Zinc finger-DNA recognition : crystal structure of a Zif268-DNA complex at 2.1 A. Science 1991;252:809–817.
19.
Wilson TE, Day ML, Pexton T, Padgett KA, Johnston M, Milbrandt J. In vivo mutational analysis of the NGFI-A zinc fingers. J Biol Chem 1992;267:3718–3724.
20.
Schulz GE, Schirmer RH. Empirical similarities between amino acid residues. In Principles of protein structure. Heidelberg:Springer-Verlag, 1984:166–205.
21.
Warner LE, Svaren J, Milbrandt J, Lupski JR. Functional consequences of mutations in the early growth response 2 (EGR2) gene correlate with severity of human myelinopathies. Hum Mol Genet 1999 (in press).

Information & Authors

Information

Published In

Neurology®
Volume 52Number 9June 1, 1999
Pages: 1827
PubMed: 10371530

Publication History

Received: September 16, 1998
Accepted: February 5, 1999
Published online: June 1, 1999
Published in print: June 1, 1999

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

V. Timmerman, PhD
From the Department of Molecular Genetics (Drs. TimmermanDe Jonghe, De Vriendt, Nelis, and Van Broeckhoven, and A. Löfgren), Flanders Interuniversity Institute for Biotechnology and Laboratory of Neurogenetics, Born-Bunge Foundation, University of Antwerp, Department of Biochemistry; the Division of Neurology (Drs. De Jonghe and Martin), University Hospital Antwerpen; the Laboratory of Neuropathology (Drs. Martin and Ceuterick), Born-Bunge Foundation, University of Antwerp, Department of Medicine, Antwerp, Belgium; and the Department of Molecular and Human Genetics (Drs. Warner and Lupski), Baylor College of Medicine, Houston, TX.
P. De Jonghe, MD, PhD
From the Department of Molecular Genetics (Drs. TimmermanDe Jonghe, De Vriendt, Nelis, and Van Broeckhoven, and A. Löfgren), Flanders Interuniversity Institute for Biotechnology and Laboratory of Neurogenetics, Born-Bunge Foundation, University of Antwerp, Department of Biochemistry; the Division of Neurology (Drs. De Jonghe and Martin), University Hospital Antwerpen; the Laboratory of Neuropathology (Drs. Martin and Ceuterick), Born-Bunge Foundation, University of Antwerp, Department of Medicine, Antwerp, Belgium; and the Department of Molecular and Human Genetics (Drs. Warner and Lupski), Baylor College of Medicine, Houston, TX.
C. Ceuterick, PhD
From the Department of Molecular Genetics (Drs. TimmermanDe Jonghe, De Vriendt, Nelis, and Van Broeckhoven, and A. Löfgren), Flanders Interuniversity Institute for Biotechnology and Laboratory of Neurogenetics, Born-Bunge Foundation, University of Antwerp, Department of Biochemistry; the Division of Neurology (Drs. De Jonghe and Martin), University Hospital Antwerpen; the Laboratory of Neuropathology (Drs. Martin and Ceuterick), Born-Bunge Foundation, University of Antwerp, Department of Medicine, Antwerp, Belgium; and the Department of Molecular and Human Genetics (Drs. Warner and Lupski), Baylor College of Medicine, Houston, TX.
E. De Vriendt
From the Department of Molecular Genetics (Drs. TimmermanDe Jonghe, De Vriendt, Nelis, and Van Broeckhoven, and A. Löfgren), Flanders Interuniversity Institute for Biotechnology and Laboratory of Neurogenetics, Born-Bunge Foundation, University of Antwerp, Department of Biochemistry; the Division of Neurology (Drs. De Jonghe and Martin), University Hospital Antwerpen; the Laboratory of Neuropathology (Drs. Martin and Ceuterick), Born-Bunge Foundation, University of Antwerp, Department of Medicine, Antwerp, Belgium; and the Department of Molecular and Human Genetics (Drs. Warner and Lupski), Baylor College of Medicine, Houston, TX.
A. Löfgren, MSc
From the Department of Molecular Genetics (Drs. TimmermanDe Jonghe, De Vriendt, Nelis, and Van Broeckhoven, and A. Löfgren), Flanders Interuniversity Institute for Biotechnology and Laboratory of Neurogenetics, Born-Bunge Foundation, University of Antwerp, Department of Biochemistry; the Division of Neurology (Drs. De Jonghe and Martin), University Hospital Antwerpen; the Laboratory of Neuropathology (Drs. Martin and Ceuterick), Born-Bunge Foundation, University of Antwerp, Department of Medicine, Antwerp, Belgium; and the Department of Molecular and Human Genetics (Drs. Warner and Lupski), Baylor College of Medicine, Houston, TX.
E. Nelis, PhD
From the Department of Molecular Genetics (Drs. TimmermanDe Jonghe, De Vriendt, Nelis, and Van Broeckhoven, and A. Löfgren), Flanders Interuniversity Institute for Biotechnology and Laboratory of Neurogenetics, Born-Bunge Foundation, University of Antwerp, Department of Biochemistry; the Division of Neurology (Drs. De Jonghe and Martin), University Hospital Antwerpen; the Laboratory of Neuropathology (Drs. Martin and Ceuterick), Born-Bunge Foundation, University of Antwerp, Department of Medicine, Antwerp, Belgium; and the Department of Molecular and Human Genetics (Drs. Warner and Lupski), Baylor College of Medicine, Houston, TX.
L.E. Warner, PhD
From the Department of Molecular Genetics (Drs. TimmermanDe Jonghe, De Vriendt, Nelis, and Van Broeckhoven, and A. Löfgren), Flanders Interuniversity Institute for Biotechnology and Laboratory of Neurogenetics, Born-Bunge Foundation, University of Antwerp, Department of Biochemistry; the Division of Neurology (Drs. De Jonghe and Martin), University Hospital Antwerpen; the Laboratory of Neuropathology (Drs. Martin and Ceuterick), Born-Bunge Foundation, University of Antwerp, Department of Medicine, Antwerp, Belgium; and the Department of Molecular and Human Genetics (Drs. Warner and Lupski), Baylor College of Medicine, Houston, TX.
J.R. Lupski, MD, PhD
From the Department of Molecular Genetics (Drs. TimmermanDe Jonghe, De Vriendt, Nelis, and Van Broeckhoven, and A. Löfgren), Flanders Interuniversity Institute for Biotechnology and Laboratory of Neurogenetics, Born-Bunge Foundation, University of Antwerp, Department of Biochemistry; the Division of Neurology (Drs. De Jonghe and Martin), University Hospital Antwerpen; the Laboratory of Neuropathology (Drs. Martin and Ceuterick), Born-Bunge Foundation, University of Antwerp, Department of Medicine, Antwerp, Belgium; and the Department of Molecular and Human Genetics (Drs. Warner and Lupski), Baylor College of Medicine, Houston, TX.
J.-J. Martin, MD, PhD
From the Department of Molecular Genetics (Drs. TimmermanDe Jonghe, De Vriendt, Nelis, and Van Broeckhoven, and A. Löfgren), Flanders Interuniversity Institute for Biotechnology and Laboratory of Neurogenetics, Born-Bunge Foundation, University of Antwerp, Department of Biochemistry; the Division of Neurology (Drs. De Jonghe and Martin), University Hospital Antwerpen; the Laboratory of Neuropathology (Drs. Martin and Ceuterick), Born-Bunge Foundation, University of Antwerp, Department of Medicine, Antwerp, Belgium; and the Department of Molecular and Human Genetics (Drs. Warner and Lupski), Baylor College of Medicine, Houston, TX.
C. Van Broeckhoven, PhD
From the Department of Molecular Genetics (Drs. TimmermanDe Jonghe, De Vriendt, Nelis, and Van Broeckhoven, and A. Löfgren), Flanders Interuniversity Institute for Biotechnology and Laboratory of Neurogenetics, Born-Bunge Foundation, University of Antwerp, Department of Biochemistry; the Division of Neurology (Drs. De Jonghe and Martin), University Hospital Antwerpen; the Laboratory of Neuropathology (Drs. Martin and Ceuterick), Born-Bunge Foundation, University of Antwerp, Department of Medicine, Antwerp, Belgium; and the Department of Molecular and Human Genetics (Drs. Warner and Lupski), Baylor College of Medicine, Houston, TX.

Notes

Address correspondence and reprint requests to Dr. V. Timmerman, Laboratory of Neurogenetics, University of Antwerp, Department of Biochemistry, Universiteitsplein 1, B-2610 Antwerp, Belgium.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Neuropathy-Associated Egr2 Mutants Disrupt Cooperative Activation of Myelin Protein Zero by Egr2 and Sox10, Molecular and Cellular Biology, 27, 9, (3521-3529), (2023).https://doi.org/10.1128/MCB.01689-06
    Crossref
  2. EGR2 gene‐linked hereditary neuropathies present with a bimodal age distribution at symptoms onset , Journal of the Peripheral Nervous System, 28, 3, (359-367), (2023).https://doi.org/10.1111/jns.12572
    Crossref
  3. A novel PMP22 insertion mutation causing Charcot–Marie–Tooth disease type 3, Medicine, 100, 11, (e25163), (2021).https://doi.org/10.1097/MD.0000000000025163
    Crossref
  4. New evidence for secondary axonal degeneration in demyelinating neuropathies, Neuroscience Letters, 744, (135595), (2021).https://doi.org/10.1016/j.neulet.2020.135595
    Crossref
  5. A de novo EGR2 variant, c.1232A > G p.Asp411Gly, causes severe early-onset Charcot-Marie-Tooth Neuropathy Type 3 (Dejerine-Sottas Neuropathy), Scientific Reports, 9, 1, (2019).https://doi.org/10.1038/s41598-019-55875-4
    Crossref
  6. Schwann Cell and the Pathogenesis of Charcot–Marie–Tooth Disease, Myelin, (301-321), (2019).https://doi.org/10.1007/978-981-32-9636-7_19
    Crossref
  7. Regulation of Peripheral Myelination through Transcriptional Buffering of Egr2 by an Antisense Long Non-coding RNA, Cell Reports, 20, 8, (1950-1963), (2017).https://doi.org/10.1016/j.celrep.2017.07.068
    Crossref
  8. EGR2 mutation enhances phenotype spectrum of Dejerine–Sottas syndrome, Journal of Neurology, 263, 7, (1456-1458), (2016).https://doi.org/10.1007/s00415-016-8153-9
    Crossref
  9. The EGR2 gene is involved in axonal Charcot−Marie−Tooth disease , European Journal of Neurology, 22, 12, (1548-1555), (2015).https://doi.org/10.1111/ene.12782
    Crossref
  10. Microprocessor Complex Subunit DiGeorge Syndrome Critical Region Gene 8 (Dgcr8) Is Required for Schwann Cell Myelination and Myelin Maintenance, Journal of Biological Chemistry, 290, 40, (24294-24307), (2015).https://doi.org/10.1074/jbc.M115.636407
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share